FDA grants priority review to efanesoctocog alfa for people with hemophilia A
The U.S. Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of hemophilia A,…
Read More...
Read More...